Comparison of survival outcomes between radiofrequency ablation and surgery for solitary hepatocellular carcinoma ≤ 5 cm （multicenter prognostic analysis）

doi:10.3969/j.issn.1009-976X.2022.04.003

Abstract

Abstract: Objective To compare the effects of radiofrequency ablation （RFA） and surgical resection （SR） on the prognosis of solitary hepatocellular carcinoma with tumor diameter ≤5 cm. Method Theclinicopathological data of patients with solitary hepatocellular carcinoma with a diameter of ≤5 cm who were admitted to Zhongshan Hospital Affiliated to Sun Yat-sen University, Tongji Hospital Affiliated to Huazhong University of Science and Technology, and Xiaogan Central Hospital from January 2015 to December 2018 and who received the above two treatments were collected. A total of 606 cases were included in this study. According to tumor diameter, the patients were divided into three subgroups:Group A （diameter≤2 cm）, Group B （2 cm<diameter≤3 cm）, Group C （3 cm<diameter≤5 cm）, among which Group A:77 patients; Group B:239 patients; Group C:290 patients. The effects of RFA and SR on the prognosis in each subgroup and the total population were compared and analyzed, and the main reasons affecting the efficacy of RFA were further explored. Results In the overall population of patients, the survival prognosis of patients in the SR group was better than that in the RFA group, and the difference was statistically significant （P<0.05）. When the tumor diameter was less than or equal to 2 cm, the clinical efficacy of SR and RFA were comparable, and there was no significant difference in overall survival （OS） and recurrence-free survival （RFS）（P>0.05）. When 2 cm<diameter≤3 cm, SR had better OS and RFS than RFA; for patients with HCC whose tumor diameter was >3cm and ≤5 cm, SR had better long-term prognosis and RFS than RFA, the difference was statistically significant （P<0.05）. Conclusion For patients with tumor diameter ≤2 cm, RFA can achieve the same clinical efficacy as SR; for patients with of 2 cm<tumor diameter ≤5 cm, SR should be given priority.

Key words: hepatocellular carcinoma, surgical resection, radiofrequency ablation, overall survival, recurrence-free survival

摘要： 目的分析射频消融（RFA）和手术切除（SR）两种治疗方式对直径≤5 cm孤立性肝细胞癌预后的影响,比较其优劣性。方法回顾性分析2015年1月至2018年12月中山大学附属中山医院、华中科技大学附属同济医院、孝感市中心医院收治的直径≤5 cm的孤立性肝细胞癌、并接受以上其中一种治疗方式的病人资料,共606例。患者分为A组（直径≤2 cm）、B组（2 cm<直径≤3 cm）、C组（3 cm<直径≤5 cm）3个亚组,其中A组：77例;B组：239例;C组：290例。调查RFA和SR两种治疗方式在各亚组和总体人群中对预后影响,并进一步分析影响RFA疗效的主要原因。结果在肝细胞癌患者总体人群中,行SR组患者的生存预后优于RFA组,差异具有统计学差异（P<0.05）。肿瘤直径≤2 cm时,SR与RFA临床疗效相当,生存预后和无复发生存无统计学差异（P>0.05）。2 cm<直径≤3 cm时,SR的生存预后和无复发生存均优于RFA;直径为>3 cm且≤5 cm的肝细胞癌患者,SR的生存预后和无复发生存优于RFA,差异存在统计学差异（P<0.05）。结论对于肿瘤直径≤2 cm患者,RFA可达到与SR一样的临床疗效;对于2 cm<肿瘤直径≤5 cm肝细胞癌患者,应优先考虑SR。

关键词: 肝细胞癌, 手术切除, 射频消融, 生存预后, 无肿瘤复发

CLC Number:

ZHANG Qiao, MO A-li, GAO Heng-yi, ZHOU Wei, Xia Feng, ZHANG Wei-liao, CHEN Wei-qiang. Comparison of survival outcomes between radiofrequency ablation and surgery for solitary hepatocellular carcinoma ≤ 5 cm （multicenter prognostic analysis）[J]. Lingnan Modern Clinics In Surgery, 2022, 22(04): 328-335.

张桥, 莫阿里, 高恒毅, 周伟, 夏丰, 张伟桥, 陈伟强. 直径不大于5 cm孤立性肝癌：射频消融与手术治疗的比较[J]. 岭南现代临床外科, 2022, 22(04): 328-335.

References

[1] Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):7.
[2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] Yang JD, Heimbach JK.New advances in the diagnosis and management of hepatocellular carcinoma[J]. BMJ, 2020, 371:m3544.
[4] von Felden J, Garcia-Lezana T, Schulze K, et al. Liquid biopsy in the clinical management of hepatocellular carcinoma[J]. Gut, 2020, 69(11):2025-2034.
[5] 孙文兵. 射频消融在肝细胞癌综合治疗中的作用[J]. 中华肝胆外科杂志, 2015, 21(9):591-595.
[6] Cucchetti A, Piscaglia F, Cescon M, et al.Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma[J]. J Hepatol, 2013, 59(2):300-307.
[7] Forner A, Reig M, Bruix J.Hepatocellular carcinoma[J]. The Lancet, 2018, 391(10127):1301-1314.
[8] Peng ZW, Lin XJ, Zhang YJ, et al.Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller:a retrospective comparative study[J]. Radiology, 2012, 262(3):1022-1033.
[9] 陈敏山,李锦清,梁惠宏,等.经皮射频消融与手术切除治疗小肝癌的疗效比较[J].中华医学杂志,2005, (2):12-15.
[10] Lafaro K, Grandhi MS, Herman JM, et al.The importance of surgical margins in primary malignancies of the liver[J]. J Surg Oncol, 2016, 113(3):296-303.
[11] Makuuchi M.Remodeling the surgical approach to hepatocellular carcinoma[J]. Hepatogastroenterology, 2002, 49(43):36-40.
[12] Shi M, Guo RP, Lin XJ, et al.Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma:a prospective randomized trial[J]. Ann Surg, 2007, 245(1):36-43.
[13] Zhou XD, Tang ZY, Yang BH, et al.Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer, 2001, 91(8):1479-1486.
[14] Llovet JM, Kelley RK, Villanueva A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
[15] Omata M, Cheng AL, Kokudo N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update[J]. Hepatol Int, 2017, 11(4):317-370.
[16] Nault JC, Sutter O, Nahon P, et al.Percutaneous treatment of hepatocellular carcinoma:State of the art and innovations[J]. J Hepatol, 2018, 68(4):783-797.
[17] Lee SH, Jin YJ, Lee JW.Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma:An analysis for nationwide cancer registry[J]. Medicine (Baltimore), 2017, 96(44):e8486.
[18] Guglielmi A, Ruzzenente A, Valdegamberi A, et al.Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis[J]. J Gastrointest Surg, 2008, 12(1):192-198.
[19] Vivarelli M, Guglielmi A, Ruzzenente A, et al.Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver[J]. Ann Surg, 2004, 240(1):102-107.
[20] Heimbach JK, Kulik LM, Finn RS, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380.
[21] Livraghi T, Lazzaroni S, Meloni F.Radiofrequency thermal ablation of hepatocellular carcinoma[J]. Eur J Ultrasound, 2001, 13(2):159-166.
[22] 高航, 翁山耕, 张翔等.小肝癌合并微血管侵犯的术前危险因素分析及预测模型构建[J]. 中华普通外科杂志, 2019, 34(11):921-924.
[23] Iguchi T, Shirabe K, Aishima S, et al.New pathologic stratification of microvascular invasion in hepatocellular carcinoma:predicting prognosis after living-donor liver transplantation[J]. Transplantation, 2015, 99(6):1236-1242.
[24] Shi M, Zhang CQ, Zhang YQ, et al.Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin[J]. World J Surg, 2004, 28(4):376-381.